Drug factors associated with increased risk for nephrotoxicity.

Slides:



Advertisements
Similar presentations
DRUGS AND THE KIDNEY DR.ALI A.ALLAWI ASSISTANT PROFESOR CONSULTANT NEPHROLOGIST.
Advertisements

Nephrotoxicity Poisonous effect of some substances both toxic chemicals and medication. Nephrotoxins are chemicals displaying nephrotoxicity.
Presented By Dr / Said Said Elshama
Allergy and Aging: An Old/New Emerging Health Issue
Allergy and Aging: An Old/New Emerging Health Issue
Nonsteroidal Anti-inflammatory Drugs, Proton Pump Inhibitors, and Gastrointestinal Injury: Contrasting Interactions in the Stomach and Small Intestine 
Medication and Acute Kidney Injury
Native ace enzyme Angiotensin-converting enzyme (EC ), or "ACE" indirectly increases blood pressure by causing blood vessels to constrict. It does.
Kidney and Drugs.
Drug Induced Nephropathy
Michael D. Gautreaux, Barry I. Freedman  Kidney International 
Nonsteroidal Anti-inflammatory Drugs, Proton Pump Inhibitors, and Gastrointestinal Injury: Contrasting Interactions in the Stomach and Small Intestine 
Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Acute kidney injury following proton pump inhibitor therapy
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use  Mei-Ling Blank, Lianne.
Viper venom for diabetic nephropathy
Frederic Rahbari-Oskoui, MD, MS  American Journal of Kidney Diseases 
Tubulointerstitial Injury Associated With Chemotherapeutic Agents
Biomarker explorations in acute kidney injury: the journey continues
Membranous nephropathy: When and how to treat
Viper venom for diabetic nephropathy
Toxic Nephropathies: Core Curriculum 2010
Manish M. Sood, MD, Amy R. Sood, Robert Richardson, MD 
Drugs Acting on the Renin-Angiotensin-Aldosterone System
Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review  Elliot B. Tapper, MD, Alan Bonder,
Renoprotective effects of vitamin D analogs
Propofol as a panacea for acute kidney injury?
Fig. 2. Evidence-based medication prescriptions
Apical membrane handling of substances, in this example aminoglycosides, by proximal tubular cells. Apical membrane handling of substances, in this example.
Kidney specific factors that enhance nephrotoxic risk are noted.
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 80, Issue 9, Pages (November 2011)
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,
Pharmacology behind Common Drug Nephrotoxicities Perazella, Mark A
Volume 84, Issue 1, Pages (July 2013)
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Volume 72, Issue 12, Pages (December 2007)
Volume 69, Issue 12, Pages (June 2006)
Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?  Areef Ishani, Charles A. Herzog,
Volume 67, Issue 1, Pages (January 2005)
The future of renoprotection: Frustration and promises
Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?  Dimitris Mavridis, PhD  American Journal.
KHA and response. KHA and response. KHA includes AKI history, BP, CKD, serum Creatinine level, Drug list, and urine Dipstick (ABCD). Exposures include.
Volume 73, Issue 5, Pages (March 2008)
Volume 68, Issue 5, Pages (November 2005)
Renin–angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center  Oliver Lenz, Alessia Fornoni  Kidney International 
Drug levels during the course of a dosing interval.
A glomerulus from a patient who developed nephrotic syndrome while receiving a nonsteroidal anti-inflammatory drug for arthritis. A glomerulus from a patient.
Immunosuppression significantly reduced all-cause mortality or risk of ESRD (A) and significantly increased complete or partial remission (B) at the end.
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications 
(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.
Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.
Changes in total drug clearance with declining kidney function relates to the extent of drug clearance by the kidney. Changes in total drug clearance with.
Basolateral transport of drugs.
Apical transport of drugs in the proximal tubule.
Patient factors that increase risk for drug-induced nephrotoxicity.
The proximal kidney tubule is the target for tenofovir-associated nephrotoxicities. The proximal kidney tubule is the target for tenofovir-associated nephrotoxicities.
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.
Potential roles of biomarkers
Algorithm for management of drug-induced acute interstitial nephritis
An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.
Proteinuria and hypertension with tyrosine kinase inhibitors
Kidney factors that enhance risk for drug-induced nephrotoxicity.
Cisplatin (Cis) nephrotoxicity is, in part, related to its uptake by proximal tubular cells. Cisplatin (Cis) nephrotoxicity is, in part, related to its.
Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.
Dr. K. Hoe MBBS DipMedSc DM (Int Med) FACP FUWI (Clinical Nephro)
Pemetrexed (Pmx) nephrotoxicity may result from proximal tubular cell uptake of drug through apical (folate receptor-α [FR-α]) and basolateral (reduced.
A urine sediment score of 0–4 is used to quantitatively evaluate AKI
Robert J. DiDomenico, PharmD, Malek G. Massad, MD 
Presentation transcript:

Drug factors associated with increased risk for nephrotoxicity. Drug factors associated with increased risk for nephrotoxicity. Medications cause kidney injury through various mechanisms. Increased exposure of the kidney on the basis of route, dose, and duration of drug exposure; drug-related immune effects (such as B-lactams, PPIs, NSAIDs, and immune checkpoint inhibitors); combined nephrotoxic drug exposure; and drug and metabolite insolubility in the urine (such as methotrexate, acyclovir, and sulfadiazine) lead to kidney injury. In addition, increased drug concentrations within tubular cells are due to transport effects (such as tenofovir and cisplatin), intracellular accumulation of certain drugs due to lack of metabolizing enzymes (such as sucrose and hydroxyethyl starch), innate direct cell toxicity (such as aminoglycosides, colistin, and amphotericin B), and intratubular cast formation from drugs interacting with uromodulin (vancomycin). ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HES, hydroxyethyl starch; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor; Tr, transporter. Mark A. Perazella CJASN 2018;13:1897-1908 ©2018 by American Society of Nephrology